SCHEMBL22845215

SCHEMBL22845215

COc1ccc(-n2c(=O)c3c(n4ncc(NC(=O)Cc5ccccc5)c24)CN(C(=O)c2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
KCNK3 O14649 1/20 0.40
ALDH1A1 P00352 6/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 4/20 0.40
MEN1 O00255 3/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
TSHR P16473 2/20 0.37
GAA P10253 2/20 0.37
NOD2 Q9HC29 1/20 0.37
POLB P06746 1/20 0.36
USP2 O75604 1/20 0.36
PKM P14618 1/20 0.36
CASP1 P29466 1/20 0.36
HTT P42858 1/20 0.36
CASP7 P55210 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845369 0.93 NPY2R (0.39) ALDH1A1MAPTLMNASMN1; SMN2TSHR
SCHEMBL22845325 0.90 MAPT (0.41) KMT2AKCNK3ALDH1A1MAPTLMNA
SCHEMBL22845211 0.89 MAPT (0.44) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL22845209 0.87 MAPT (0.42) KMT2AKCNK3ALDH1A1MAPTLMNA
SCHEMBL22845433 0.87 MAPT (0.42) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL24173921 0.86 DHODH (0.42) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL22845328 0.84 ALDH1A1 (0.40) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL22845429 0.84 ALDH1A1 (0.43) KMT2AALDH1A1MAPTLMNAMEN1
SCHEMBL22845206 0.84 POLB (0.41) KMT2AKCNK3ALDH1A1MAPTLMNA
SCHEMBL22845326 0.83 MAPT (0.46) KMT2AALDH1A1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL KMT2A 3917/4885KCNK3 2506/4885ALDH1A1 648/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL KMT2A 3917/4885KCNK3 2506/4885ALDH1A1 648/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL KMT2A 3917/4885KCNK3 2506/4885ALDH1A1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.